Privia Health Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Privia is a physician-enablement company supporting medical groups and value-based care (VBC) programs. It operated in 14 markets.
Financial and operating performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $415.2 million | $386.3 million | +7.5% |
| Gross profit | $93.4 million | $83.0 million | +12.5% |
| Operating income | $0.8 million | $6.7 million | −87.7% |
| Net income attributable to Privia | $3.0 million | $7.3 million | −59.3% |
| Adjusted EBITDA | $19.9 million | $16.9 million | +18.1% |
| Cash and cash equivalents, at period end | $351.1 million | $311.2 million | Prior-year period-end balance |
| Net cash used in operating activities | $33.1 million | $13.4 million | Use increased |
- Gross margin was approximately 22.5%, versus 21.5%; operating margin was approximately 0.2%, versus 1.7%. Adjusted EBITDA margin, as defined by the company, was 21.0% of Care Margin, compared with 20.1%.
- Revenue mix shifted: fee-for-service patient-care revenue rose 20.6% to $274.8 million; capitated revenue fell 34.4% to $51.3 million; shared-savings revenue grew 8.0% to $47.5 million. Care-management fees increased 23.9% to $10.6 million.
- Implemented Providers increased 17.3% to 4,359, and Attributed Lives increased 10.2% to 1.143 million. Practice Collections grew 7.4% to $707.7 million.
- Operating cash use reflected working-capital movements, including a $55.3 million increase in accounts receivable; provider liability rose $24.2 million. Investing cash use was $5.7 million, compared with $24.9 million in Q1 2023. Cash declined $38.4 million during the quarter.
- At March 31, total current assets were $728.1 million and current liabilities $403.8 million. Provider liability was $350.3 million. No borrowings were outstanding under the $125 million revolving credit facility, which expires in November 2028; lease liabilities were $7.5 million in total.
Material changes and management commentary
- Effective January 1, 2024, approximately 19,800 attributed lives moved from at-risk capitation, reported gross, to shared savings, reported net, following renegotiation of certain contracts. Management cited Medicare Advantage regulatory and utilization headwinds and said the revised structures may provide more favorable economics and potential positive contribution margin in 2024. This transition contributed to lower reported capitated revenue; comparisons of revenue and related costs may therefore reflect presentation as well as underlying business changes.
- Management attributed FFS growth primarily to provider additions and higher visit volumes; shared-savings growth to more Medicare-program attributed lives and continued VBC performance. New-market entry contributed to growth, while associated costs weighed on Platform Contribution Margin, down to 47.1% from 49.3%.
- Operating expenses rose 9.2%, faster than revenue. General and administrative expense increased 23.8%, partly reflecting higher stock-based compensation and $2.2 million of increased non-recurring expenses. Stock-based compensation was $11.9 million versus $5.4 million.
- Net income declined despite higher revenue and Adjusted EBITDA, with higher platform, administrative and other operating costs contributing to lower operating income. Net interest income was $3.0 million, compared with $1.8 million.
Outlook, risks and contingencies
- The filing gives no numerical full-year revenue, earnings or cash-flow guidance. Management expects available cash and operating cash flows to support short- and long-term needs, while noting that growth, spending, acquisitions and financing needs could change requirements. The company cautions that Q1 results are not indicative of full-year results.
- Key risks include healthcare regulation and compliance, payer and Medicare/Medicaid changes, Medicare Advantage utilization and contract economics, reliance on medical-group relationships and the athenahealth EMR platform, competition, expansion execution, provider workforce availability and compensation, and privacy and cybersecurity obligations.
- Provider liability depends on estimates of incurred-but-not-reported claims and other actuarial assumptions; actual settlements may differ. Three major payers represented 54% of Q1 revenue combined, and the largest represented 30%.
- The company reported no material commitments or contingencies, no off-balance-sheet arrangements, and no material changes to the risk factors in its 2023 Form 10-K. It is involved in ordinary-course legal matters, including medical malpractice and consumer claims, which management does not expect to have a material adverse effect. Disclosure controls were deemed effective.
Important facts for investors to verify
- Track the economics and reporting effects of the approximately 19,800 lives shifted from gross capitation to net shared savings, including medical costs and contribution margin.
- Assess operating cash use, receivables growth and provider-liability estimates against subsequent collections and claims development.
- Monitor whether expense growth, especially platform costs, G&A and stock-based compensation, moderates and supports operating-margin improvement.
- Review payer concentration and the company’s exposure to Medicare Advantage, regulatory changes and contract renewals.
- Evaluate non-GAAP measures alongside GAAP results; Adjusted EBITDA excludes stock-based compensation and other items, and the filing reports no numerical full-year guidance.